March 2012 - Zurich
Adam Michael and Jamie Hooper represented the Abchurch Life Sciences practice by attending the first Sachs Biotech Investment Forum of the New Year in Zurich. As always the event was excellently attended with both private and listed biotech companies, a broad spectrum of the finance community, representatives from the medical profession and the occasional PR practitioner.
The format of the Sachs Forum gives attendees the best possible chance to maximise their time in Zurich with an efficient one-to-one meeting system, themed panel discussions, and networking facilities throughout the day. With over 200 companies attending, and a strong contingent of European life science investors, delegates at Sachs were kept very busy.
The panel sessions stimulated quality debate for both the day and evening networking (over a glass wine and canapés), covering such topics as; the resurgence of platforms technologies over products; the latest interactions between big pharma and biotech; and the current popularity of the French biotech industry with investors.
The one-to-one meeting system enables delegates to pre-arrange meetings with potential collaborators and investors, or to just help increase someone’s knowledge on a particular technology. Frequently compared to speed dating the platform gives attendees a fast, sharp opportunity to interact with numerous delegates in a more structured setting than the networking hall. The half hour sessions keep meetings to the point.
While times are still tough in life sciences, with capital hard to raise, and public markets shying away from life sciences, events like the Sachs CEO Forum give companies in the sector a real opportunity to present their case to investors and partners and maintain momentum across the industry.
One thing is for certain: the Swiss venue for the conference continues to garner strong support from both the vibrant and sophisticated finance community, and the local, world-leading, pharmaceutical industry.
Follow us on Twitter @AbchurchComms